3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Paraproteinemias
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Specimen Handling
79
Bevacizumab
66
Drug Therapy
65
Cisplatin
64
Carboplatin
63
Magnetic Resonance Spectroscopy
61
Radiotherapy
57
Cyclophosphamide
55
Gemcitabine
54
pembrolizumab
53
Oxaliplatin
50
Capecitabine
50
toripalimab
42
Paclitaxel
41
tislelizumab
40
Standard of Care
40
Biopsy
37
fludarabine
36
Fluorouracil
35
venetoclax
33
Injections
33
Blood Specimen Collection
31
Immune Checkpoint Inhibitors
30
anlotinib
29
Nivolumab
29
Surgical Procedures, Operative
28
Irinotecan
27
Docetaxel
27
Dexamethasone
27
Leucovorin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
1 year
×
Clear all
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled